Schedule dependent potentiation of antitumor drug effects by α-difluoromethylornithine in human gastric carcinoma cells in vitro

Sam C. Barranco, Courtney Townsend, Barbara Y. Ho, Karen J. Reumont, Steven K. Koester, Pamella J. Ford

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

A clone of human gastric cancer cells (AGS-6) and the parental line (AGS-P) from which it was isolated were used in cell survival studies to determine whether pretreatment for 24, 48 or 72h with α-difluoromethylornithine (DFMO, 5mM) would increase the cell's sensitivity to 5-Fluorouracil (5FU), Adriamycin (Adria), 1-(2-chloroethyl)-3-(4-methyl cyclohexyl)-1-nitrosourea (MeCCNU), or Bleomycin (Bleo). Generally, the AGS parental cells were most sensitive to the anticancer agents after exposures to DFMO. However, there was no way to predict in advance from DFMO-induced changes in ornithine decarboxylase (ODC), polyamine or cell kinetics values, how long an exposure to DFMO was required before sensitization to an anticancer agent occurred. The degree of potentiation for a single drug was variable from time to time during exposure to DFMO, and broad differences in the sensitizations were demonstrated among the four anticancer drugs. The AGS-6 clone exhibited little or no increased sensitivity as a result of pretreatment with DFMO, even though the DFMO-induced reductions in ODC and polyamine values in these cells were similar to those produced in the more sensitive parental line.

Original languageEnglish (US)
JournalInvestigational New Drugs
Volume8
Issue number1 Supplement
DOIs
StatePublished - Mar 1990

Fingerprint

Eflornithine
Antineoplastic Agents
Stomach
Appointments and Schedules
Carcinoma
Ornithine Decarboxylase
Polyamines
Clone Cells
Bleomycin
Fluorouracil
Pharmaceutical Preparations
Doxorubicin
Stomach Neoplasms
Cell Survival
In Vitro Techniques

Keywords

  • αDFMO
  • cell killing
  • heterogeneity
  • polyamines
  • stomach cancer

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this

Schedule dependent potentiation of antitumor drug effects by α-difluoromethylornithine in human gastric carcinoma cells in vitro. / Barranco, Sam C.; Townsend, Courtney; Ho, Barbara Y.; Reumont, Karen J.; Koester, Steven K.; Ford, Pamella J.

In: Investigational New Drugs, Vol. 8, No. 1 Supplement, 03.1990.

Research output: Contribution to journalArticle

Barranco, Sam C. ; Townsend, Courtney ; Ho, Barbara Y. ; Reumont, Karen J. ; Koester, Steven K. ; Ford, Pamella J. / Schedule dependent potentiation of antitumor drug effects by α-difluoromethylornithine in human gastric carcinoma cells in vitro. In: Investigational New Drugs. 1990 ; Vol. 8, No. 1 Supplement.
@article{5f007979e9bf462d945ff13e611e8101,
title = "Schedule dependent potentiation of antitumor drug effects by α-difluoromethylornithine in human gastric carcinoma cells in vitro",
abstract = "A clone of human gastric cancer cells (AGS-6) and the parental line (AGS-P) from which it was isolated were used in cell survival studies to determine whether pretreatment for 24, 48 or 72h with α-difluoromethylornithine (DFMO, 5mM) would increase the cell's sensitivity to 5-Fluorouracil (5FU), Adriamycin (Adria), 1-(2-chloroethyl)-3-(4-methyl cyclohexyl)-1-nitrosourea (MeCCNU), or Bleomycin (Bleo). Generally, the AGS parental cells were most sensitive to the anticancer agents after exposures to DFMO. However, there was no way to predict in advance from DFMO-induced changes in ornithine decarboxylase (ODC), polyamine or cell kinetics values, how long an exposure to DFMO was required before sensitization to an anticancer agent occurred. The degree of potentiation for a single drug was variable from time to time during exposure to DFMO, and broad differences in the sensitizations were demonstrated among the four anticancer drugs. The AGS-6 clone exhibited little or no increased sensitivity as a result of pretreatment with DFMO, even though the DFMO-induced reductions in ODC and polyamine values in these cells were similar to those produced in the more sensitive parental line.",
keywords = "αDFMO, cell killing, heterogeneity, polyamines, stomach cancer",
author = "Barranco, {Sam C.} and Courtney Townsend and Ho, {Barbara Y.} and Reumont, {Karen J.} and Koester, {Steven K.} and Ford, {Pamella J.}",
year = "1990",
month = "3",
doi = "10.1007/BF00171979",
language = "English (US)",
volume = "8",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "1 Supplement",

}

TY - JOUR

T1 - Schedule dependent potentiation of antitumor drug effects by α-difluoromethylornithine in human gastric carcinoma cells in vitro

AU - Barranco, Sam C.

AU - Townsend, Courtney

AU - Ho, Barbara Y.

AU - Reumont, Karen J.

AU - Koester, Steven K.

AU - Ford, Pamella J.

PY - 1990/3

Y1 - 1990/3

N2 - A clone of human gastric cancer cells (AGS-6) and the parental line (AGS-P) from which it was isolated were used in cell survival studies to determine whether pretreatment for 24, 48 or 72h with α-difluoromethylornithine (DFMO, 5mM) would increase the cell's sensitivity to 5-Fluorouracil (5FU), Adriamycin (Adria), 1-(2-chloroethyl)-3-(4-methyl cyclohexyl)-1-nitrosourea (MeCCNU), or Bleomycin (Bleo). Generally, the AGS parental cells were most sensitive to the anticancer agents after exposures to DFMO. However, there was no way to predict in advance from DFMO-induced changes in ornithine decarboxylase (ODC), polyamine or cell kinetics values, how long an exposure to DFMO was required before sensitization to an anticancer agent occurred. The degree of potentiation for a single drug was variable from time to time during exposure to DFMO, and broad differences in the sensitizations were demonstrated among the four anticancer drugs. The AGS-6 clone exhibited little or no increased sensitivity as a result of pretreatment with DFMO, even though the DFMO-induced reductions in ODC and polyamine values in these cells were similar to those produced in the more sensitive parental line.

AB - A clone of human gastric cancer cells (AGS-6) and the parental line (AGS-P) from which it was isolated were used in cell survival studies to determine whether pretreatment for 24, 48 or 72h with α-difluoromethylornithine (DFMO, 5mM) would increase the cell's sensitivity to 5-Fluorouracil (5FU), Adriamycin (Adria), 1-(2-chloroethyl)-3-(4-methyl cyclohexyl)-1-nitrosourea (MeCCNU), or Bleomycin (Bleo). Generally, the AGS parental cells were most sensitive to the anticancer agents after exposures to DFMO. However, there was no way to predict in advance from DFMO-induced changes in ornithine decarboxylase (ODC), polyamine or cell kinetics values, how long an exposure to DFMO was required before sensitization to an anticancer agent occurred. The degree of potentiation for a single drug was variable from time to time during exposure to DFMO, and broad differences in the sensitizations were demonstrated among the four anticancer drugs. The AGS-6 clone exhibited little or no increased sensitivity as a result of pretreatment with DFMO, even though the DFMO-induced reductions in ODC and polyamine values in these cells were similar to those produced in the more sensitive parental line.

KW - αDFMO

KW - cell killing

KW - heterogeneity

KW - polyamines

KW - stomach cancer

UR - http://www.scopus.com/inward/record.url?scp=0025347468&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025347468&partnerID=8YFLogxK

U2 - 10.1007/BF00171979

DO - 10.1007/BF00171979

M3 - Article

VL - 8

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 1 Supplement

ER -